• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

First-time generic drug approvals, April 2008

Article

Generic drugs approved by FDA (through April 2008) including cefuroxime for oral suspension, pramipexole tablets, alendronate once-daily tablets, and alendronate once-weekly tablets.

Cefuroxime for oral suspension, 125 and 250 mg/5 mL (equiv to Ceftin for oral suspension)

RANBAXY

Pramipexole tablets, 0.125, 0.25, 0.5, 1, and 1.5 mg (equiv to Mirapex tablets)

Alendronate once-daily tablets, 5, 10, and 40 mg, and once-weekly tablets, 35 mg (equiv to Fosamax tablets)

TEVA

Alendronate once-weekly tablets, 70 mg (equiv to Fosamax tablets)

TEVA, BARR

Related Content
© 2024 MJH Life Sciences

All rights reserved.